PICATO (ingenol mebutate gel, 0.015% and 0.05%) – Product Withdrawal in Canada due to Potential Increased Risk of Skin Cancer

At Health Canada’s request, LEO Pharma Inc. is withdrawing Picato from the Canadian market. This follows a safety review by the Department, which concluded that use of Picato may be associated with an increased risk of non-melanoma skin cancer, and that the benefits of using Picato no longer outweigh its potential risks.